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Transforming growth factor-f3 (TGFf3) is a secreted protein that is involved in the
regulation of many cellular processes and has been implicated as a factor in cancer cell
invasion and metastasis. Studies have indicated that different TGFj3 isoforms may exert
differential effects on cancer cells during different stages of the disease, however very
little is known about the expression patterns of the 3 isoforms in prostate cancer. Non
traditional signaling pathways including P13-kinase have been associated with TGFj3-
mediated effects on cancer cell invasion and metastasis. Whether or not TGFf3 isoforms
play a differential role in migration and invasion of prostate cancer, and act through P13 -
Kinase, has not been investigated. In the present study, we have carried out expression
analysis of TGFf3 isoforms and signaling components in cell line models representing
different stages of prostate cancer and studied the differential effects of specific isoforms
on migratory, invasive behavior and induction of the P13-Kinase and MAP-Kinase/ERK
pathways. TGFf31 and TGFI33 were expressed in all prostate cell lines, with TGFI33
increasing in metastatic DU145, PC3 and PC3M cell lines. TGFI31 and TGFI33 induced
motility and invasive behavior in PC3 cells, with TGFf33 being more potent in inducing
invasive behavior. TGFf33 caused a significant increase in the phosphorylation of AKT
(pAKT473), a downstream target of P13-Kinase, in PC3 cells. LY294002, a P13-kinase
inhibitor, blocked this induced migration and phosphorylation of AKT. Inhibitors of
TGFf3RI (SB43 1524) and Smad3 (SIS3) blocked TGFf3 isoform induced motility and
TGFI3 isoform induced pAKT473. There was no differential isoform effect on the
phosphorylation of ERK (pERK). PD98059, a MEK inhibitor of MAP-Kinase/ERK, did
inhibit TGFf3 isoform induced migration and pERK, but did not affect isoform induced
pAKT473. Furthermore, TGFI3 isoforms phosphorylate both Smad2 and Smad3 in a
similar manner in PC3 cells. Based on these results, we conclude that TGFf33 is
expressed in metastatic prostate cancer cell lines and is involved in induction of invasive
behavior in these cells. Furthermore, these effects of TGFI33 are mediated via the P13-
Kinase pathway and are TGFf3RI and Smad3 dependent.
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Prostate cancer is the most commonly diagnosed cancer in men, with the chances
of diagnosis rapidly increasing after the age of 50.’ It is estimated that in 2012, roughly
242,000 new cases will be diagnosed, and nearly 28,000 deaths will occur due to prostate
cancer (Figure 1). 2 Though prostate cancer is known to grow at a slow rate, risk factors
such as diet and late detection can lead to increased fatality rates Men diagnosed with
low-grade, localized and regional prostate cancers have a 100% 5-year survival rate,
however, men with late-stage, metastatic prostate cancers that have spread to distant areas
such as lymph nodes, bones and other organs only have a 31% 5-year survival rate. ~ This
dramatic decrease in survival due to metastasis is cause for increased research in the area
of invasion and metastasis.
Transforming growth factor-f3 (TGFJ3) is a secreted cytokine involved in the
regulation of many cellular processes and has been implicated as a factor in cancer
formation and progression leading to increased migration and invasion ~ TGFI3 exerts
pleiotropic effects on numerous cellular functions that include differentiation,
proliferation, motility and extracellular matrix (ECM) production in many normal cell
types.6’ 71n normal epithelial cells and early stage cancers, TGFj3 inhibits cell proliferation
and acts as a tumor-suppressor.4’8’9 However, in later stages of many cancers, the tumor
cells become resistant to growth inhibitory effects of TGFI3. In these cells, TGFI3 can act
as a tumor promoter due to its role in stimulating angiogenesis, epithelial to mesenchymal
2
transformation (EMT), or promoting the degradation of ECM; all of which aid in invasion
and metastasis. 5, 10, 11
The three TGF~3 isoforms, TGFf31, TGFI32 and TGFI33, share a 70-80% sequence
homology in most organisms and are expressed throughout most mammalian tissues •6, 7,
12 Of the three isoforms, TGFI31 is the most commonly studied and tends to be
ubiquitously expressed among cell lines and in diseased tissues such as cancer 13, 14
numerous in vitro studies, all three isoforms bind to the same receptors and exert similar
biological effects on target cells. 15 However, TGFI3 isoforms can have non-redundant
specific effects during development as indicated by gene knock-out studies.’6’9 Binding
affinity studies show that the three isoforms signal by binding to TGFj3RI and
TGFf3RII.2° However, TGFI32 differs from TGFI31 and TC-F133 in that it binds to
TGFI3RII with an affinity that is 100-1000 fold lower and requires TGF(3R111 (13-glycan)
to promote receptor assembly with TGF~32. 12, 21-25 Additionally, crystal structure of
TGFI3RII-TGFI33 complex showed that interfacial residues of TGFI33 are identical to
TGFI31 but are different from TGFf32 at three positions. 26 These studies suggest that
although both TGFI3 1 and TGFI33 share a significant homology, receptor binding affinity
and can exert similar biological effects on target cells, they may retain the ability to have
non-redundant differential effects.
Earlier studies have indicated that individual TGF~ isoforms may exert
differential effects on cancer cells during different stages of the disease. In one such
study, TGFf33 increased the invasiveness of endometrial carcinoma cells via a P13-
Kinase-dependent pathway, and these effects were distinct from those of TGFI3 1. 27
prostate cancer, there is very little known about the expression levels of the three
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isoforms, specifically TGFI33, in prostate cancer cell lines and clinical tissue samples.
Evidence indicates that TGFI33 expression increases 2 fold in prostate tumors and that the
TGFf33 gene is over-expressed in an androgen-independent derivative of prostate cancer
cell line compared to the androgen-dependent parental cell line. 28
Recent studies have suggested the involvement of the phosphatidylinositol 3-
kinase (P13-Kinase) pathway in TGFI3-mediated effects on cancer cell invasion and
metastasis. P13-Kinase has been shown to play an integral role in many cellular processes
including cell proliferation, growth and survival in both normal and diseased tissues ~29, 30
Activating mutations of the P13-Kinase pathway and loss of PTEN are common in many
types of cancers and are associated with tumor progression. 31 It has been shown that
TGFI3 can activate PI3-Kinase, as determined by increased phosphorylation of AKT, a
downstream target of P13-Kinase. 32-36 Prior studies have also revealed that TGFI3
isoform-specific effects on the P13-Kinase pathway can be either dependent or
independent of Smad signaling depending on the experimental conditions and cellular
context.27’35’36 The P13-Kinase pathway has also been implicated as a contributing
pathway to TGFI3 induced EMT as well as fibroblast proliferation and morphological
transformation, all precursors to invasion and metastasis ~36 Whether or not TGFJ3
isoforms play a differential role in invasion and metastasis of prostate cancer, and act
through non-Smad pathways such as P13-Kinase, is still unclear.
Therefore, it is important to determine what differential effect, if any, TGFf3
isoforms have on the induction of the P13 -Kinase pathway and their role in invasion and
metastasis in prostate cancer.
Preliminary results from our laboratory led us to the hypothesis that the TGFI33
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isoform may play a more significant role in the invasive behavior of late stage prostate
cancer epithelial cells. Furthermore, the action of TGFI33 may also have a significantly
higher effect on the phosphorylation of AKT and be mediated via the P13-Kinase
Pathway. To test this hypothesis, we asked at the following questions:
1. Do the TGFI3 isoforms have a differential effect on the migratory and invasive
properties of different prostate cancer cells?
2. Does this differential effect of the TGFf3 isoforms use the canonical TGF~3
pathway and br other pathways involved in invasion and metastasis of cells
including the P13-kinase/AKT pathway?
CHAPTER 2
REVIEW OF THE LITERATURE
2.1 The Prostate
The prostate is a male accessory reproductive exocrine gland whose function is
the secretion of a slightly acidic seminal fluid that aids in the production of semen ~
This gland is described as having three distinct areas categorized as the peripheral, central
and transition zones, of which the peripheral area contains the majority of epithelial cells
and where most prostate carcinomas develop •37,40 The prostate consists of two cell
types, stromal and epithelial. The stroma consists of mostly smooth muscle cells which
are involved in the production of growth factors, whereas epithelial cells contain luminal
secretory, basal, and neuroendocrine cells, all of which aid in the function of the prostate.
37,41 The development of this male reproductive organ is cependent upon the expression
and production of growth factors, receptors and androgens, including testosterone during
fetal development. Androgens are essential for the growth and function of the prostate
gland during development and have been shown to regulae growth factor gene
expression in the prostate.42~45 Multiple growth factors prcduced in response to androgens
including epidermal growth factor (EGF) and insulin-like growth factors (IGF) can help
stimulate prostatic epithelial growth.4649 Transforming growth factor-f3 (TGF~3), on the
other hand, exhibits an inhibitory role on the prostatic stromal and epithelial cell growth
in multiple prostate samples. ~ 50-53 One study postulates that TGFI3 plays an important
role in the stromal-epithelial interactions during prostate development based on the
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differential expression of two TGF~3 isoforms in rat ventral prostate and that testosterone
does not affect this expression. ~ The exact mechanism by which TGFI3 isoforms affect
prostate development and their hormonal regulation, however, remains unclear.
2.2 Prostate Cancer
Prostate cancer transpires and progresses as the result of accumulated genomic
mutations that led to unchecked cellular growth and survival advantage of the mutated
and dividing cells~54 The incidence of prostate cancer has been on a steady increase in the
United States with age, ethnicity and a positive family history of the disease being the
most common risk factors. 55-62 Though many types of cancer grow and spread rapidly,
prostate cancer is known for its slow progression and occurs at a higher incidence rate
among men over the age of 50.63 More recently, prostate cancer has been shown to be a
racial disparity in that African American men have the highest rate of incidence of any
population in the world, with an incidence rate of 231.9 to 146.3 versus Caucasians per
100,000 individuals and a mortality rate of 56.3 to 23.6 versus Caucasians per 100,000
individuals. 64 This suggests that prostate cancer is heavily determined not just by age,
but by genetic, environmental and possibly socio-economic factors as well.
Most prostate cancers arise from multiple genetic shifts such as suppression or
promotion within genetic polymorphisms, tumor suppressor/promoter genes, growth
factor production and receptor signaling. Of these conventional tumor suppressor genes, a
mutated PTEN, a negative regulator of the P13-Kinase pathway, has been shown to be
involved in the progression of prostate cancer. 65,66 Multiple growth factors including
IGF- 1, Interleukins and TGFf3 have been implicated in the regulation of prostate cancer
cell proliferation, progression and/or metastasis as well. 67-73
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2.3 Metastasis
Metastasis of a primary tumor is the spread of cancerous cells from one part of the
body to another, leading to secondary tumor formation and growth. ~ Frequently,
secondary tumor sites can occur in vital organs or systems, with some of the most
common cancer secondary sites being lung, brain, liver, and bone, eventually leading to
increased medical complications and decreased survival rate. ~ Prostate cancer, however,
almost exclusively metastasizes to the bone. 76 Metastasis, being the final stage in tumor
evolution, is thought to be the cause for the bulk of cancer deaths that are associated with
primary tumors.
During cancer progression, there are several general mechanisms that occur
during the metastatic cascade including tumor formation and angiogenesis, cell
attachment, invasion and growth of the metastases. ‘~ During this process, a single cell
can become genetically mutated in which cellular responses ordered to correct these
mutations are no longer capable of doing so. When these mutated cells are not corrected,
they can proliferate, forming a possible carcinoma. Once the carcinoma, or primary
tumor, has gained the size and necessary components, it begins to degrade the basement
membrane or extracellular matrix of the surrounding tissues and invades into other
nearby compartments. If the carcinoma becomes malignant, cells break free from the
primary tumor, enter the blood stream and disseminate throughout the body (Figure 2).
This leads to extravasion to the lymph nodes, organs and/or bone, increasing the rate of
poor prognosis and mortality. ‘~‘~‘
Many different molecular barriers occur between a newly mutated and migratory
tumor cell and its distant new home in other vital organs and tissues. 78 This invasive
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difficulty is mirrored by the fact that less than 0.05% of circulating tumor cells are
actually able to become stable secondary site metastases.79 Each of these hurdles
involved in metastasis requires numerous specific cell signaling and molecular
interactions by the cancer cell itself~ the surrounding extracellular matrix (ECM) and
stromal cells. This can occur via cell-ECM contact, cell to cell contact or by secreted
factors such as matrix metalloproteinases (MMPs) and transforming growth factor-13. 5, 80-
83
2.4 Transforming Growth Factor-n
One cytokine that has been the focus of cancer metastasis studies is transforming
growth factor-n (TGFI3). Originally discovered in the conditioned media of sarcoma virus
transformed mouse fibroblasts, TGFI3 has been shown to be a secreted protein that is
involved in the regulation of many cellular processes and has been implicated as a factor
in cancer formation and progression. 4, 5,84 It is part of the TGFI3 super family which
includes TGFI3 ligands, bone morphogenic proteins (BMP’s), activins and nodals. 85 The
TGF-f3 ligands are pleiotropic cytokines that play an integral role in numerous cellular
functions that include differentiation, proliferation, motility and extracellular matrix
(ECM) production in many normal cell types and can act as a potent anti-tumor agent. 6,7,
86 However, in diseases such as cancer, TGFI3 can also act as a tumor promoter by its role
in stimulating angiogenesis, epithelial to mesenchymal traisformation (EMT), or
promoting the degradation of ECM; all of which aid in invasion and metastasis. ~ 10, 11
The exact mechanisms by which TGF)3 switches from tumor suppressing to tumor
promoting cytokine are currently under investigation.
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2.4.1 TGF~ Isoforms
As seen in many gene arrays and oncomine data sets, the TGFI3 isoforms, TGFI31,
TGFI32 and TGFI33, are expressed throughout many mammalian tissues. 6,7, 12 All three
of these cytokines are secreted in the ECM in a latent form (L-TGFI3) and become
biologically active when cleavage or conformational change occurs by acidic
microenvironment and factors such as plasmin and matrix metalloproteinases (MMPs). 87,
88 Of the three isoforms, TGFI31 is the most commonly studied and tends to be
ubiquitously expressed among cell lines and in diseased tissues such as cancer. 13, 14 Until
recently, TGFI32 and TGFf33 have been thought to carry out the same biological functions
as TGFf31. 15 However, to assume all 3 isoforms perform the same functions in cells by
default can be misleading, since TGFj33 is structurally and biologically unique compared
to other isoforms ,15 TGFj33 shares an 86% similarity to TGFI3 1, while sharing a 91%
similarity to TGFj32 (Figure 3). 15 Though TGFf32 and TGFI33 share the highest
similarity, TGF132 binding to its Receptor II requires a co-receptor, whereas TGF13 1 and
TGFI33 bind in the same manner, and through different residues than TGFI32. 89 Other
observations indicate TGFI31 and TGFI33 ligand/receptor complexes differ in that the
complex may engage signaling pathways differently, leading to different biological
activities. Nuclear Magnetic Resonance (NMR) data shows that the active domain of
TGF13 1 is structurally ordered, whereas TGF133 is structurally disordered, suggesting that
TGF133 can adopt a more “open” state which may allow for a more open receptor/ligand
complex.26’9093 This strengthens the idea that different isoforms may engage multiple
pathways in different ways regardless of its structural similarities. TGF13 1 is most
commonly studied isoform in many biological systems, whereas TGFf33 studies are
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considerably less. TGFI3 1 null mice exhibit vasculogenic defects and result in death of
approximately 50% of the null embryos by day ten, giving the ligand an important role in
fetal development. 16 TGFI32 also tends to be ubiquitously expressed among tissues,
however null mice exhibit abnormalities in cardiopulmonary, urogenital, neural and
skeletal systems ~17 TGFI33 null mice experience 100% mortality due to a cleft palate and
the inability to suckle effectively.18’ 19 The differences in biological features that TGFf3
isoform null mice exhibit is a clear isoform specificity in fetal development. The
differential role that these three isoforms have on tumor progression and metastasis is still
unclear.
2.4.2 Signaling Pathway
In the canonical TGFI3 pathway, there are 3 types of receptors, Type I, II and III of which
receptor I and II are serine/threonine kinases .~‘ There are at least five known
mammalian type II receptors: transforming growth factor f3 receptor II (TGFf3RII), activin
receptor II and IIB(ActRII, ActRIIB),bone morphogenic protein receptor II (BMPRII),
and anti-mullerian hormone receptor 2 (AMHRII) and seven type I anaplastic lymphoma
kinase receptors (ALKs 1—7) that can interact through a variety of combinations, though
in most cells, the ligands signal through the TGFI3RII-ALK 5 complex. 13 The type III
receptor, which is considered an accessory receptor, incluies 13-glycan and endoglin
(CD 105). ~ Once TGFI3 ligands become biologically active, they bind to the membrane
bound Type II receptor. It is at this time that TGFI3 downstream target Smad proteins
begin recruitment to the receptor complex. The Smad protein family consists of 8
members including Smads 1, 2, 3, 5, 8 (receptor-activated Smads, R-Smads), Smad 4
(common-mediator Smads, Co-Smads) and Smad 6 and 7 (inhibitory Smads, 1-Smads). 96
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A majority of the Smad proteins are widely expressed in many cell types and are
important for all TGFI3 activity.97 Once ligand binding to Type II receptor is complete,
Type II recruits and phosphorylates the Type I receptor to form an active ligand-receptor
complex, leading to downstream phosphorylation of Smad2/3, substrates for ALKs 4, 5
and 7. 13 Smad2/3 forms a complex with the common mediator Smad4, which can then
translocate and accumulate in the nucleus, where it can carry out gene regulation via
binding to gene promoters and regulating transcription (Figure 4) 6, 15,98
2.4.3 TGF~ isoforms in normal development
The TGFf3 isoforms are multifunctional cytokines that inhibit cellular
proliferation of many cell types, including those from epithelial origin and play important
roles in embryonic development and tissue homeostasis . ~ TGF~3 is heavily involved in
extracellular matrix synthesis and modulation of the immune response including wound
repair processes and inflammatory reactions.100102 It is the inappropriate functioning and
changes in expression of these cytokines that has been implicated in several diseases
including carcinogenesis. Because all three isoforms require activation before they can
exert biological activity, it is thought that this activation is a crucial regulatory step in
controlling their affects. Multiple gene knockout and overexpression studies suggest that
precise regulation of each isoform is essential for survival. The TGFf3 signaling pathway
has both important extracellular and intracellular phases, all of which can lead to
modifying the expression of specific sets of target genes. As seen in multiple gene
expression profiles and studies, TGFf3 can act as a tumor suppressor, targeting genes that
regulate cell proliferation such as p21, E2F-1 and c-myc and apoptosis such as Fas and
Bcl-xL. 103-105 As a tumor promoter, however, TGFI3 not only reverses its tumor-
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suppressive effects on genes involved with proliferation and apoptosis, but also targets
genes involved in angiogenesis such as VEGF, MMP-2, MMP-9, as well as immune
response suppressor genes in multiple cell types and diseased tissues.’°3’°6
2.4.4 TGF~ isoforms in cancer
TGFf3 1 has been shown to be a potent tumor suppressor in many cells .~
However, it has also been shown in later stages of the disease that the presence of TGFI3 1
is required for disease progression, giving it a tumor-prom~ting role.’°7 In early stages of
tumorigenesis, TGFI3 acts in a similar manner as it does in normal epithelial cells,
continuing as an influential anti-proliferative ligand via inhibition of cell growth,
induction of apoptosis and cell cycle arrest.105 During the latter stages of the disease,
however, TGFf3 can achieve tumor-promoting properties. Though the main hallmarks of
cancer are increased mutations in multiple proteins and pathways, TGF~ tends to keep its
functionality as well as an increase in its expression. 108 This increase in expression of
ligands and receptors can lead to production of an environment that promotes tumor
invasion and metastasis including remodeling and/or degradation of the ECM due to
increased production of MMPs.’°5’ 109-112 Unfortunately, a majority of studies performed
to determine the role of TGFI3 in tumor progression have focused solely on the TGFf3 1
isoform. Observations of TGFf33 in cancer progression have been scarce and indecisive.
One study that gives TGFI33 a possible role in cancer metastasis showed that TGFI33
increased the invasiveness of endometrial carcinoma cells which was P13K-dependent. 27
TGFj33 expression levels have been reported in several different cancers from clinical
studies. In colon carcinomas biopsies, the expression of TGFI33 was uniform across
tumor tissue stages as well as normal tissue samples, suggesting it is unlikely that the
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isoform plays a role in its’ progression. 113 In breast carcinomas, however, clinical
studies reveal an increase in TGFf33 expression, correlating with a decrease in overall
survival.”4’ 115 In prostate cancer, there is very little known about the expression levels
of the three isoforms, specifically TGFI33 in numerous cell lines and clinical tissue
samples. One study of 14 prostate adenocarcinomas showed low to no expression of the
TGFI33 isoform, with only 3 of the 14 showing any expression at all. 116 Another study,
however, indicates TGFI33 expression increases 2 fold in prostate tumors. 117 Other
studies indicate a down regulation of TGFI33 in prostate carcinomas compared to normal
tissue, suggesting that increased expression of the isoform is correlated with suppression
of prostate cancer. 118122 With such contradicting evidence, it is important to explore the
role of these isoforms in established prostate cell lines.
2.5 The Phosphatidylinositol 3-kinase (P13-Kinase) pathway
There has been a great deal of recent evidence that also suggests the role of many
non-traditional pathways involved in TGFI3 mediated invasion and metastasis. One such
pathway, the phosphatidylinositol 3-kinase (P13-Kinase) pathway, has been shown to
have an integral part in many cellular processes including cell proliferation, growth and
survival in both normal and diseased tissues. 29,30 In the classical pathway, PI3-Kinases
can be divided based on their functions and structure into 3 classes: Class I (IA and TB),
Class II, Class III, with Class I being the most commonly studied and understood in
mammalian cells. 123, 124 P13K is most notably activated by receptor tyrosine kinases
(RTK’s) and G-protein coupled receptors (GPCR’s), which are stimulated by ligands
such as growth factors and hormones. 125 Activation of P13-Kinase by upstream receptors
leads to downstream activation of the pathway, beginning with subsequent conversion of
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phosphatidylinositol-4,5 bisphosphate (PIP2) to phosphatidylinositol-3,4,5 bisphosphate
(PIP3) via phosphorylation. 125-127 Once phosphorylated, PIP3 can bind to
phosphoinositide-dependant kinase 1(PDK1) and AKT/protein kinase B. 128 This leads
to membrane recruitment of AKT and phosphorylation of AKT at sites Thr 308 by PDK1
and Ser 473 by PDK2 (Figure 5) 129131 Once full activation of AKT occurs, it can move
to the nucleus and/or cytoplasm where it can activate or inhibit numerous targets that are
involved in metabolism, cell survival, and cell cycle progression, making AKT the most
important downstream target of the P13-Kinase pathway. 30 As mentioned earlier, it has
been shown that TGFf3 can activate P13K, as shown by increased phosphorylation of
AKT and this activation of AKT appears to be Smad2/3 independent. 35,36 The P13-
Kinase pathway has also been implicated as a contributing pathway to TGFj3 induced
EMT as well as fibroblast proliferation and morphological transformation, all precursors
to invasion and metastasis. 36 This evidence indicates the multiple roles TGFI3 plays in
the activation or suppression of the P13-Kinase pathway. Whether or not TGFI3 isoforms
play a role in invasion and metastasis, and if this role is Smad-dependent or independent,
remains unclear. In Van Themsche, Mathieu et al. 2007, they were able to show that only
TGFf33 could increase the invasiveness of the endometrial carcinoma cell lines and that
this increased invasion was triggered via TGFI33 activation of P13-Kinase and AKT. The
activation of P13-Kinase/AKT led to a Smad-dependent up-regulation of XIAP and
induction of MMP-9. There is very little, if any information available on the isoform
specific roles of TGFf3 and P13-Kinase pathway in prostate cancer.
One important antagonist of the P13-Kinase pathway is Phosphatase and tensin
homolog deleted on chromosome 10 (PTEN). PTEN is known to be an important factor
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in maintaining homeostasis and keeping the P13-Kinase pathway in check. In the P13-
Kinase pathway, PTEN hydrolyzes PIP3 to PIP2, antagonizing any downstream activity
including phosphorylation of AKT. 132 A PTEN mutation leads to an inactive form,
allowing high activation of the P13-Kinase pathway and subsequently AKT. 125, 133
Mutations of the P13-Kinase pathway and loss of PTEN are common in many types of
cancers and is associated with tumor progression. 31 It is thought that this mutation,
along with overexpression of P13-Kinase and activating mutations of the pllOa subunit
of the P13-Kinase protein lead to the initiation and progression of tumorigenesis. 134-137
2.6 TGFP and the P13-Kinase Pathway: A link?
There are numerous findings to suggest a role for TGFf3 in P13-Kinase signaling.
It has been shown that TGFI3 can activate P13-Kinase, as shown by increased
phosphorylation of AKT, however the exact mechanism by which it does so is still
elusive. 3236 In an effort to elucidate how TGFI3 activates the PI3-Kinase pathway,
studies have shown that this activation of AKT can be independent of Smad2/3 and that
both TGFI3RI and TGFI3RII kinase activity can associate with the p85 subunit of the P13-
Kinase protein, thus activating the pathway. 138-142 There is also evidence to suggest a
physical interaction between Smad3 and AKT. 143, 144 Formation of this complex is
inhibited by TGFf3 stimulation allowing for Smad3 phosphorylation, Smad4 binding and
translocation to the nucleus. 143, 144 These findings suggest some interaction between the
TGFI3 pathway and the P13-Kinase/Akt pathway that may be tightly regulated in normal
cell types and differentially active in diseased cells. Multiple studies have also linked the
P13-Kinase pathway as a contributing pathway to TGFf3 induced EMT as well as
fibroblast proliferation and morphological transformation. 36 Whether or not TGFI3
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isoforms play a differential role in invasion and metastasis, and act through non-smad
pathways such as P13-Kinase, is still unclear.
2.7 The Mitogen-Activated Protein Kinase (MAPK) Pathways
Other non-Smad pathway that has been implicated in the progression of cancer
are the mitogen activated protein kinase (MAP-Kinase) pathways. 145, 146 MAP-Kinases
are Serine/Threonine kinases that affect a wide range of cellular responses. 147 Multiple
MAP-Kinase pathways are expressed in all mammalian cells and regulate gene
expression, motility and apoptosis. 147 There are 14 known MAP-Kinases that are
arranged in several conventional groups including ERK1 and 2 (extracellular signal-
regulated kinases 1 and 2), INK1, 2 and 3 (c-Jun amino (N)-terminal kinasesi, 2 and 3),
p38 isoforms , and ERK5. 147-150 These conventional MAPKs consist of a cascade of
three conserved, sequentially acting Serine/Threonine kinases. MAPKK Kinase
(MAPKKK) is activated via extracellular stimuli leading to the activation of MAPK
kinase (MAPKK) and finally MAP-Kinase (MAPK). ERK1 and 2 are the most notably
studied and defined of the MAP-Kinases and is known to be activated in response to
growth factors including EGF, PDGF and in response to insulin. 151-153 ERK1 and 2
MAP-Kinase model contains MAPKKKs (A-Raf, B-Raf, Raf- 1, Mos and TPL-2),
MAPKKs (MEK1 and MEK2), and the MAPKs (ERK1 and ERK2) (Figure 6). This
cascade tends to be activated via receptor tyrosine kinase (RTK) activity. 147 PD98059,
an inhibitor of MEK 1 and 2 in the ERK signaling cascade, interact with the inactive
unphosphorylated MEK1 and MEK2, leading to inhibition of its activity. 154 Upon
extracellular activation of the ERK1 and 2 MAP-Kinase pathway, ERK1 and 2 can
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accumulate in the nucleus and activate a number of substrates associated with cell
proliferation, differentiation and survival.’55
The ERK1 and ERK2 pathway is often up-regulated in human tumors leading
increased proliferation, angiogenesis and metastasis. 156 TGFf3 is known to signal
through the MAP-Kinase pathways. 105, 138 Rapid activation by TGFI3 of ERK MAP
Kinase has been observed in many cell types including epithelial, breast cancer cells and
fibroblasts whereas other studies suggest a delayed activation by TGFI3 occurring hours
after the initial stimulation. 146, 157159 Though the exact mechanisms by which TGFI3
activates ERK are still under investigation, studies suggest a role of the TGFj3 receptors.
TGFj3 receptors are defined as Serine/Threonine kinases, however they do contain several
tyrosine phosphorylation sites that undergo both autophosphorylation and activation upon
ligand binding, allowing for the recruitment of downstream effectors known to activate
MAP-Kinases. 160-162 ERK activation has also been shown to be a necessary non-smad
pathway involved in TGFf3 induced EMT through both Smad-dependent and Smad
independent effects, specifically in late stage tumor progression including loss of the
ECM and metastasis. 163-166 Little is known, however, about the effects of specific TGFI3




Recombinant human TGFI31 and TGFI33 were purchased from R & D systems
(Minneapolis, MN). Inhibitors of TGFI3RI (SB43 1542) and Smad3 (SIS3) were
purchased from Tocris Bioscience (Ellisville, MO) and EMD Biosciences (Gibbstown,
NJ), respectively. Specific inhibitors of P13-Kinase (LY294002) and MAP-Kinase
MEK1/2 (PD98059) were purchased from Sigma-Aldrich KSt. Louis, MO). The
antibodies against pAKT~473’ AKT (PAN), pSmad2, pSmad3, Smad2/3 and pERK
(phospho p44/42 ERK1/2) were purchased from Cell Signaling Technology (Beverly,
MA). Total-ERK1/2 antibody was purchased from Promega (Madison, WI). Antibodies
against TGFI3 1, 2 and 3 were purchased from Peprotech (Rocky Hill, NJ). Anti-13-Actin
(clone AC- 15) antibody was purchased from Sigma-Aldrich (St. Louis, MO). Anti-rabbit
IgG HRP was purchased from Bio Source (Camarillo, CAi and Anti-mouse IgG HRP
was obtained from Promega (Madison, WI). Matrigel and invasion inserts were
purchased from BD Biosciences (Bedford, MA). The HEMA 3 stat dye was purchased
from Fisher (Pittsburgh, PA).
Cell Lines and Cell Culture
Prostate cell lines LNCaP (prostate carcinoma), DU 145 (prostate carcinoma), PC3
(prostate adenocarcinoma), RWPE 1 (epithelial cells from histologically normal adult
human prostate), RWPE2 (immortalized epithelial cells were derived from RWPE-1 cells
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by transformation with Ki-ras using the Kirsten murine sarcoma virus (Ki-MuSV)), PZ
HPV7 (immortalized epithelial cells from histologically normal adult human prostate)
and MvlLu (mink lung epithelial cells) were acquired from American Type Cell Culture
Collection (Rockville, MD). PC3M cells (metastatic derivative of PC3) were kindly
provided by Dr. Girish Shah (University of Louisiana). All Cells were cultured in
recommended growth medium at 37°C with 5% CO2 and 100% humidity. DU145, PC3,
PC3M and MvlLu cells were cultured in Eagle’s minimum essential medium (MEM)
with Earle’s salts with 0.1 mM of the essential amino acid supplements as described
previously. 167, 168 LNCaP cells were maintained in RPMI 1640 containing 4 mM
glutamine and 50 p~g/ml gentamycin. Both MEM and RPMI media (Mediatech, Herndon,
VA) were supplemented with 5% fetal bovine serum (FBS; HyClone, South Logan,
Utah). RWPE1, RWPE2 and PZ-HPV7 were cultured in keratinocyte serum free medium
(KSFM) containing 50 ~ig/ml gentamycin (Invitrogen) and with 0.05 mg/ml bovine
pituitary extract and 5ng/ml EGF.
RNA isolation, cDNA Synthesis and RT-PCR
For RT-PCR analysis, cells were seeded (5 x 1 05/well) into 6-well plates
overnight. Total RNA was isolated from the cells using TRIzol (Invitrogen) followed by
chloroform extraction and isopropanol precipitation and quantified by optical density
reading at 260 nm. 0D260/0D280 ratios were used for quality assessment of RNA
preparations. Total RNA (2 jig) were reverse transcribed as previously described. 169 RT
PCR reactions were performed on 1-Cycler IQ (BioRad, Hercules, CA). RT-PCR
reactions were performed according to procedures described previously. 167 Gene
encoding ribosomal protein L-19 was used as an internal control. All gene-specific
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primers were designed with the assistance of the computer program Beacon Designer 5.0
(PremierBiosoft International, Palo Alto, CA) which was set to exclude regions of cross-
homology against the non-redundant set of human genes from GenBank, EMBL, and
DDBJ database sequences) and to exclude regions of significant secondary RNA
structure. When possible, primer sets were designed to span long introns to avoid
amplification of genomic DNA. Sequences of all primers used in RT-PCR experiments
are shown in table 1. The PCR products were visualized on 1-2% agarose gels stained
with ethidium bromide or on 4% SFR agarose gels (Amresco, Solon, OH). Analyses of
PCR products were carried out in three independent experiments using different cell
preparations.
TGFP Treatments
To determine the effects of TGFI3 isoforms on phosphorylation of AKT, Smad2, Smad3
and the phosphorylation of ERK, DU145, PC3, and LNCaP cells were cultured in 6 well plates
(5x105 cells/well) in 5%FBS/MEM and allowed to attach overnight. Cells were serum starved for
2 hours and incubated with or without TGFf3RI inhibitor (SB43 1542 : 5~tM), Smad3 Inhibitor
(S153 : 3~tM), P13-Kinase inhibitor (LY294002: 10 jiM) or MAP-Kinase MEK1/2 (PD98059:
25uM)for 30 minutes. Phosphatase inhibitor (SodiumVanadate; 200 jiM) was added 10 minutes
prior to the treatment. Cells were then treated with TGFf3 1 or TGFI33 (Sng/ml) over various time
points. Cells were washed twice with ice-cold phosphate-buffered saline and lysed in lysis buffer
(Cell Signaling Technology, Beverly, MA) containing 20 mM Tris-HC1 (pH 7.5), 150 mM NaC1,
1mM Na2EDTA, 1mM EGTA, l%Triton, 2.5mM sodium pyrophosphate, 1mM f3-
glycerophosphate, 1mM Sodium Vanadate, 1 jig/mi leupeptin and 1X protease inhibitor cocktail
(Calbiochem, San Diego, CA). Protein concentrations were determined by the Lowry HS assay
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using the Bio-Rad DC Protein Assay kit (Bio-Rad) according to the instructions provided by the
manufacturer.
Western Blot Analyses
Cell lysates were mixed with Laemmli’s buffer (62.5 mM Tris, pH 6.8, 2% SDS,
5% j3-mercaptoethanol and 10% glycerol) and individual samples (25-50 ~tg proteins)
were subjected to SDS-PAGE in 8 or 10% gels and transferred to PVDF membranes
(Millipore, Billerica, MA). The membranes were blocked for 1 hr in TBST (50 mM Tris,
pH 7.5, containing 0.15 M NaC1, 0.05% Tween 20) containing 5% fat free skim milk.
The blots were then incubated with appropriate dilutions of specific primary antibodies
overnight at 4°C in TBST containing 5% bovine serum albumin (BSA). After washing,
blots were incubated with anti-rabbit or anti-mouse immunoglobulins coupled to
horseradish peroxidase (dilution 1:10,000) in blocking buffer (TB ST with 5% milk) for
lh and washed in TBST for lhr. The blots were developed in SuperSignal West Pico
chemiluminescent substrate (Thermo Scientific) or ECL Prime (Amersham) for 3
minutes, exposed to an X-ray film and visualized by autoradiography. Western blots for
AKT (Pan), Smad2/3, ERK1/2 and 13-actin were carried out in parallel as loading
controls. The relative intensities of specific protein bands were determined by
QuantityOne image analysis software.
Scratch Wound Assay
The migratory properties of DU145 PC3, and LNCaP cells were measured using a
scratch wound assay. Cells were plated in 6-well plates (5x105 cells/well) in MEM with
5% FBS and cultured overnight. Before treatment, wells were scratched down the middle
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with a 200 ~il pipette tip. Culture media were replaced with MEM containing 0.1%FBS
and cells were treated with TGFf31 or TGF~33 (1 ng/ml) with or without specific inhibitors
of TGFI3RI (SB431542: 51iM), Smad3 (SIS3: 31iM), P13-Kinase (LY294002: 10 jiM) or
MAP-Kinase (PD98059: 25jiM). Cells were allowed to migrate across the scratch for
48h. Images of the scratch area were recorded at three random spots at 0 and 48h. The
migrating cells were counted using a standard size field for each image. Statistical
analysis was performed using students t-test (n=3) with SigmaPlot Analysis Software.
Invasion Assay
The invasive properties of DU145 and PC3 were measured using the BD BioCoat
Matrigel Invasion inserts. Inserts (BD Biosciences) were coated with 50 jil of a 1:4
Matrigel/Medium dilution (BD Biosciences) and allowed to solidify at 37°C for 1 hr.
Cells were resuspended (5x104 cells/ml) in MEM with .1% FBS and 500 jil of cell
suspension was added to each insert. Cells were treated with or without specific inhibitors
of TGFI3RI (SB43 1542: 5jiM), Smad3 (SIS3: 3jiM) or P13-Kinase (LY294002: 10 j.tM)
followed by TGFI31 or TGFI33 (.1, 1 or 10 ng/ml) and allowed to invade through a porous
membrane coated with Matrigel at 37°C for 48h. Matrigel and non-invading cells were
removed via scrubbing. Invading cells on the membrane were fixed in 3.7%
paraformaldehyde and stained using the HEMA3 stain set (Fisher). Pictures were taken in
five different fields for average number of invading cells to be determined. Statistical
analyses were performed using students t-test (n=4) with SigmaPlot Analysis Software.
TGF~ Bioassay
MvlLu mink lung epithelial cells were used as target cells for the detection of any
differences in recombinant TGFI3 isoform bioactivity using CellTiter 96 Non-Radioactive
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Cell Proliferation Assay (Promega). 170, 171 MvlLu were seeded at 5 x 1 ~ on 96-well
plates in DMEM containing 5% FBS. After allowing cells :o attach overnight, medium
was replaced with fresh DMEM + 5% FBS and recombinant TGFI31 or TGF)33 was
added at 1 and 10 ng/ml and incubated for 48 hours at 37°C. After 48 hrs, medium was
again replaced with DMEM + 5% FBS and 15 ul Dye Solution and incubated at 37°C in
the dark for 4 hrs. Following 4 hr incubation, SolubilizationlStop Solution was added and
incubated for 1 hr. Absorbance was read at 570 nm using a 96-well plate reader.
Statistical analysis was performed using student t-test (n=3) with SigmaPlot Analysis
Software.
MTT Assay
PZ-HPV7, DU145 and PC3 cells were used as target cells for the detection of any
differences in the cell viability after treatment with recombinant TGFf3 isoforms using
CellTiter 96 Non-Radioactive Cell Proliferation Assay (Promega).’70’ 171 Cells were
seeded (5 x 1 ~ cells/well) in 96-well plates in appropriate media. After allowing cells to
attach overnight, media was replaced with fresh media and recombinant TGFj3 1 or
TGFJ33 were added at the concentration of 1 and 10 ng/ml and incubated for 48h at 37°C.
After 48h, media was again replaced with media containing 15 j.tl Dye Solution and
incubated at 37°C in the dark for 4h. Following 4h incubation, solubilizationlstop
solution was added and incubated for lh. Absorbance was read at 570 nm using a 96-well
plate reader. Three independent experiments were carried out with similar results.




4.1 Gene Expression of TGF~ isoforms, Receptors and Smad proteins in prostate
cell lines
Gene expression of TGFj3 isoforms and receptors in prostate cells was determined
by RT-PCR across several established cell lines, (table 2) with L- 19 used as a control
(Fig. 7). TGFI31 mRNA was expressed across all seven cell lines (PZ-HPV7, RWPE1,
RWPE2, DU145, PC3, PC3M, LNCaP cells); however the expression was substantially
lower in LNCaP cells. TGFI32 mRNA was detected in six of the seven cell lines with low
expression in PZ-HPV7, RWPE1 and RWPE2 cells. A slight increase was detected in
cancer cell lines DU145, PC3 and PC3M, however there was no detectable expression of
TGFj32 in LNCaP cells.
TGFf33 expression was relatively low in normal prostate epithelial cell line PZ
HPV7 and in LNCaP cells, and was slightly higher in RWPE1 and RWPE2 cells, as well
as in DU145 cells. The highest expression of TGFf33 was found in PC3 and PC3M cells,
both metastatic prostate cancer cell lines.
TGFI3RI mRNA was expressed throughout all seven cell lines, with LNCaP cells
again having the lowest expression. TGFf3RII was expressed in PZ-HPV7, RWPE1,
RWPE2, DU145, PC3 and PC3M cells; however it was not detected in LNCaP cells.
TGFI3RIII was detected at low levels in PZ-HPV7, RWPE1, RWPE2, DU145, PC3, and
PC3M cells, however it was not detected in LNCaP cells. The mRNA expression of
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Smad2 and Smad3 (R-Smads), Smad4 (Co-Smad) and Smad7 (1-Smad) were detected in
all seven cell lines.
4.2 Protein Expression of TGF~ isoforms and TGF~RII in prostate cell lines
Western blot analysis was performed to determine relative protein abundance of
TGFI3 isoforms (TGFf31, 2 and 3) in total cell lysates from PZ-HPV7, RWPE1, RWPE2,
DU145, PC3 and PC3M cells (Fig. 8) and for TGFI3RII in cancer cell lines LNCaP,
DU145 and PC3 cells (Fig. 9). All cells were cultured under standard growth conditions.
TGFI31 (5Okd precursor protein) was expressed across all cell lines, while TGFI32 (25kd
mature protein) was detected only in PC3 and PC3M cells. TGFf33 (5Okd precursor
protein) was detected in all cell lines, with high levels in metastatic cell lines DU145,
PC3 and PC3M cells. TGFI3RII protein was detected in DU145 and PC3 cells, however it
was absent in LNCaP cells. LNCaP cells were included in future assays as a negative
control to rule out non-specific effects of TGFI3 isoforms as LNCaP cells do not contain
mRNA or protein for signaling through TGFI3RII.
These studies showed an increase in both gene and protein expression of TGFf33
in metastatic cell lines DU145 and PC3 cells indicating a possible autocrine role of this
isoform in migration and invasion. Therefore, for further studies, DU145 and PC3 cell
lines were selected to determine migratory and invasive potential in response to
exogenous TGFI31 and TGFf33. Both DU145 and PC3 cells express all of the TGFJ3
ligands, receptors and Smad proteins.
4.3 Effects of TGF~ isoforms on proliferation of Mink Lung Cells
In order to rule out bioactivity differences in the recombinant TGFI3 isoform
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proteins used for treatments, a standard Mink Lung Cell (MV 1 Lu) bioassay was
performed to determine dose dependant and isoform specific effects of recombinant
TGFI3land TGFI33 on cell growth. Figure 10 shows that even though both TGFI31 and
TGFI33 significantly inhibited MvlLu cell proliferation at .1, 1 and 10 ng/ml, none of the
treatments were statistically different from each other, suggesting both recombinant
isoforms have similar bioactivity at different dilutions.
4.4 Effects of TGF~ isoforms on proliferation of prostate cell lines
TGFI3 is known to inhibit proliferation in normal prostate epithelial cells.73 The
effects of TGFI31 and TGFI33 on the proliferation of immortalized normal epithelial (PZ
HPV7) cells were determined using MTT assay in order to rule out possible differences
in the biopotencies of recombinant proteins. Figure 11 shows that both TGFI31 and
TGFf33 significantly inhibited PZ-HPV7 cell proliferation at both 1 and 10 ng/ml, with no
differences in the potencies of the two isoforms. We also studied the effects of the two
isoforms on proliferation of DU145 cells. As shown in figure 12, both isoforms inhibited
growth of these cells at 1 and 10 ng/ml and again, showed no differences in potencies.
PC3 cells did not respond to the growth inhibitory effects of either isoform (Fig. 13).
This proliferation data, along with the gene and protein expression data strengthen
the need to use DU145 and PC3 cells as a possible model for the mechanistic switch of
TGFI3 from tumor-suppressor to tumor-promoter and to help elucidate the possible
signaling differences between the TGFI3 isoforms.
4.5 Differential effects of TGF~ isoforms on migration of prostate cancer cells
The effects of TGFI31 and TGF~33 on migration of metastatic prostate cancer cell
lines PC3, DU145 and LNCaP were determined using a scratch wound assay. PC3,
27
DU 145 and LNCaP cells were treated with either TGFI3 iscform and allowed to migrate
according to established procedures. As shown in Figure 14, both TGFI3 isoforms caused
an increase in the migration of PC3 cells. However, TGFI33 effects were 2.1 fold (n=3)
higher than those ofTGFf3l on number of migrating cells (See Fig. 23; P <0.01). Both
TGFI3 isoforms had no effects on the migration of DU145 and LNCaP cells under similar
experimental conditions (Figure 15 and 16, respectively).
4.6 Differential effects of TGF~ isoforms on invasion of prostate cancer cells
As shown in Figure 17, both TGFI31 and TGFI33 increased invasiveness of PC3 cells.
TGFI31 had a significant effect on invasion at .lng/ml (P <0.05), which declined at both
lng/ml and lOng/mi doses. However, TGFI33 caused significantly higher invasion of PC3
cells compared to TGFI31 at lng/ml (P <0.05) and lOng/nJ (P < 0.01) doses (Fig. 18).
Both TGFf3 isoforms had no effect on invasiveness of DU ~ 45 cells under identical
experimental conditions (Fig. 19).
These results, along with similar migration data, suggest a differential role of TGFf33
versus the ubiquitously expressed TGFf3 1. In order to determine how these isoforms are
differentially increasing both migration and invasion, it is important to determine what
role, if any, the canonical TGFI3 pathway plays in these results.
4.7 The role of TGF~ffl and Smad3 in TGF~ isoform induced migration and
invasion
To determine whether TGFI3 1 and TGFf33 effects on cell migration and invasion
are mediated by classical TGFf3 signaling pathway, PC3 cells were treated with TGFI31 or
TGFI33 in the presence of specific inhibitors of TGFf3RI. As shown in Figure 20, TGFI3RI
inhibitor (SB43 1542) blocked TGFI31 and TGFI33 inducec. migratory effects on PC3
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cells. Smad3 Inhibitor (SIS3) also blocked migration of PC3 cells induced by TGFf3
isoforms as well (Fig. 21). The migrating cells were counted using a standard size field
for each image. Statistical analysis was performed using students t-test (n=3) with
SigmaPlot Analysis Software (Fig. 23).
TGFI3RI inhibitor (SB43 1542) and Smad3 Inhibitor (SIS3) also blocked the
effects of TGFI3 isoforms on invasive behavior of PC3 cells (Fig. 24 and 25,
respectively). Pictures were taken in five different fields for average number of invading
cells to be determined. Statistical analyses were performed using students t-test (n=4)
with SigmaPlot Analysis Software (Fig. 27).
Based on these results, we determined that even though the TGFI3 isoforms act
differentially on cells during the migration and invasion process, both isoforms require a
minimum of the canonical TGFI3 pathway machinery including the TGFI3RI and the
Smad3 protein. This suggests that any differential activity of TGFI3 1 or TGFI33 may be
occurring via separate pathways that are traditionally involved in the metastatic cascade
leading to migration and invasion. One such pathway that we deemed necessary to
explore is the P13-Kinase pathway.
4.8 Differential effects of TGF~ isoforms on migration are mediated by P13-Kinase
pathway
To determine if TGFI3 isoform-induced migration is mediated via the P13-Kinase
pathway, scratch wound assays were performed in the presence or absence of a specific
P13-Kinase inhibitor (LY294002: 10 jIM). PC3 Cells were treated with TGFI31 or TGFf33
(ing/mi) and allowed to migrate across a scratch for 48h. Pictures were taken at Ohr and
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48hr and number of migrating cells was determined by counting. As shown in Figure 22,
P13-Kinase inhibitor (LY294002) blocked both TGFI31 and TGFf33 induced migratory
behavior in PC3 cells. Statistical analysis was performed using students t-test (n=3) with
SigmaPlot Analysis Software (Fig. 23).
4.9 Differential effects of TGF~ isoforms on invasion are mediated by P13-Kinase
pathway
Similar to previous migration studies, invasion assays were performed to
determine if TGFI3 isoform-induced invasion is mediated via the P13-Kinase pathway as
well. Invasion assays were performed in the presence or absence of a specific P13-Kinase
inhibitor (LY294002: 10 ~tM). PC3 Cells were treated with TGFf31 or TGFI33 (lng/ml)
and allowed to invade a matrigel-coated insert for 48h. Pictures were taken at Ohr and
48br and number of invading cells was determined via staining. As shown in Figure 26,
P13-Kinase inhibitor (LY294002) also blocked the effects of both isoforms on the
invasion of PC3 cells. Statistical analysis was performed using students t-te~t (n~4) with
SigmaPlot Analysis Software (Fig. 27).
4.10 Differential effects of TGF~ isoforms on activation of P13-Kinase pathway
To determine whit effects TGFI3 isoforms have on the P13-Kinase pathway and
phosphorylation of AKT (pAKT), we first wanted to determine levels basal pAKT~4’3 in
our panel of prostate cell lines. As shown in Figure 28, our normal prostate epithelial cell
lines show no detectable levels of pAKTs~473, however both PC3 and LNCaP show
detectable pAKTs~473, with basal phosphorylation higher in LNCaP. It is important to
note that though DU145 is considered a metastatic cell line, it indeed has no detectable
phosphorylation of AK.T under these ~iormal conditions. This data again demonstrates
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why the DU 145 and PC3 cell lines are an excellent model to determine the differential
role of TGFf3 isoforms on the P13-Kinase pathway. PTEN, a negative regulator of the
P13-Kinase pathway, is active in the DU145 cell line, but is mutated and biologically
inactive in PC3 cells and absent from LNCaP cells altogether 172475~ It is these
differences in the cell lines that will help to elucidate what effect and/or association, if
any, the TGFI3 isoforms have with P13-Kinase pathway and its downstream target
pAKT~’473
To determine if TGFI3 isoforms differentially activate the P13 -Kinase pathway and
phosphorylation of AKT (pAKT), PC3 cells were treated with either TGFf3 1 or TGFI33
(5ng/ml) for specific time points and probed for pAKT~473, a downstream target of P13-
Kinase. Both TGFI3 isoforms induced an increase in the phosphorylation of AKT~’473
over several time points in PC3 cells. TGF~33 was more effective than TGFI3 1 in
increasing pAKT~473 (Fig. 29). Based on the most significant time points, we then
compared TGFI3 isoform induced pAKT~473 in DU145, PC3 and LNCaP cells 15 and 60
mm after treatment. TGFI3 isoforms again induced an increase in the phosphorylation of
AKT ser473 in PC3 cells (Fig. 30). Once again, TGFI33 was more effective at inducing the
phosphorylation of AKT ser473 with a significant (3.7 fold; n = 3) increase at 60 mm as
determined by densitometry using 13-actin as a control (Fig. 31). However, neither TGFf3
isoform increased pAKT ser473 levels in DU145 (Fig. 32) or LNCaP cells (Fig. 33) at both
time points. Once again, DU145 cells showed no detectable phosphorylation of AKT
even upon treatment with TGFI3 isoforms, whereas LNCaP cells showed detectable, yet
unchanged levels of pAKT~473
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4.11 The role of TGF~RI, Smad3 and P13-Kinase on TGF~ isoform-induced
phosphorylation of AKT~473
To determine whether TGFI3 1 and TGFf33 induced pAKT ser473 are mediated by
TGFf3RI, Smad3 or P13-Kinase pathway, PC3 cells were treated with a TGFI3RI inhibitor
(SB43 1542), Smad3 inhibitor (SIS3) or P13-Kinase inhibitor (LY294002) followed by
TGFI31 or TGFI33 (5ng/ml). Cell lysates were collected and analyzed for pAKT ser473,
Total AKT (pan) and 13-actin. TGF~3RI inhibitor (SB43 1542) blocked TGFI3-induced
pAKT ser473 (Fig. 34) as did Smad3 inhibitor (SIS3) (Fig. 35). P13-Kinase inhibitor
(LY294002) also blocked basal and TGFI3-induced accumulation of pAKT ser473 in PC3
cells (Fig. 36).
4.12 The role of TGF~RI, Smad3 and P13-Kinase on TGFfI isoform-induced
phosphorylation of Smad 2 and Smad 3
To determine any TGFI3 isoform-specific effects on the phosphorylation of Smad
2 and Smad 3, we again treated PC3 cells with either TGFI31 or TGFI33 (5ng/ml) for 60
mm. As shown in figure 37, both TGFf31 and TGFI33 induce the phosphorylation of Smad
2 and Smad 3 and at similar intensities. We also looked at the phosphorylation of Smad 2
and Smad 3 upon treatment with the same inhibitors. TGFI3RI inhibitor SB43 1542
blocked the effects of both TGFI3 1 and TGFI33 on phosphorylation of Smad2 and Smad3
(Figure 38). Smad 3 inhibitor SIS3 blocked effects of both isoforms on Smad3
phosphorylation without affecting the phosphorylation of Smad2 (Figure 39). P13-Kinase
inhibitor LY294002 did not influence Smad2 or Smad3 phosphorylation in response to
both isoforms (Figure 40).
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4.13 The effects of TGF~ isoforms on the activation of the Mitogen-Activated
Protein Kinase extracellular signal-regulated kinases 1/2 (ERK1/2)
In order to determine any TGFI3 isoform-specific differential activation of the MAP
Kinase ERK1/2, we looked at the phosphorylation of ERK1/2 (p44/42) in response to
TGFI3 treatment. TGFf3 has been shown to activate the MAP-Kinase pathway via
phosphorylation of ERK1/2. 162 As seen in figure 41, TGFI31 induces a slight increase in
the phosphorylation of ERK2 (p42) whereas TGF~3 does not. We do note that in PC3
cells under these conditions, we only see phosphorylation of ERK at the p42 position,
however when EGF is added, we see phosphorylation at both p44/p42 sites. When an
inhibitor of MAP-Kinase (PD98059) is added, all phosphorylation of ERK1/2 is blocked
as expected. Both Total ERK1/2 and f3-actin were used as loading controls.
To determine whether the ERKIMAP-Kinase pathway and the P13-Kinase pathway
have any crosstalk upon activation by treatment with TGFI3 isoforms, we again treated
PC3 cells with an inhibitor of ERKIMAP-Kinase MEK1 and 2 (PD98059) followed by
TGFI31 or TGFf33 and probed for the pAKT ser473 antibody. As seen in figure 42, blocking
the MEK1/2 did not affect the TGFI3 isoform-induced phosphorylation of AKT,
suggesting that there is no cross-talk or requirement for ERKJMAP-Kinase for TGF~
induced activation of the P13-Kinase pathway.
4.14 The role of the Mitogen-Activated Protein Kinase pathway in TGF~ isoform
induced migration
Since the ERKIMAP-Kinase pathway has been implicated in the progression of
cancer in multiple biological processes, we wanted to determine whether having an active
ERK/MAP-Kinase was necessary for cell motility at both a basal and TGFI3 induced
level. We found that by blocking the MAP-Kinase pathway with an inhibitor of
ERKJMAP-Kinase MEK1/2 (PD98059), we inhibit all migration of PC3 cells with and




This study is the first of its kind to systematically determine the expression of all
TGF~3 isoforms, receptors and Smads simultaneously in several prostate cell lines.
Though previous studies have shown the presence of TGFf3 isoforms and machinery in
different cancers including prostate tissues and cell lines, none have looked at the relative
mRNA and protein expression levels in numerous prostate cell lines under the same
experimental conditions. We have shown that TGFI31 is ubiquitously expressed at both
the mRNA and protein level in both normal and metastatic prostate cell lines. This
suggests that any differential effects seen in the normal versus metastatic cell lines may
be due to changes in expression of other TGFf3 isoforms. Alternatively, post translation
activation may play a role in changing effects of TGF~ El during different stages of
prostate cancer. We show an increase of both TGFI32 and TGFI33 in metastatic prostate
cell lines, however TGFI32 protein expression changes were only seen in PC3 cells. The
steadiest change was seen in TGFf33 expression, with it increasing consistently in the
more metastatic cell lines. This may indicate a specific role of TGFf33 in the metastatic
phenotype. This differential role for this isoform is supported by similar high expression
of TGFI33 in breast carcinomas correlating with decreased overall survival rate 114, 115 and
that TGFJ33 increased invasiveness of endometrial carcinoma cells. 27114, 115
Based on our expression data, we deemed it important to focus on two of the
isoforms, TGFI31 and the lesser studied TGFI33. As mentioned earlier, TGFI33 shares less
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similarity to TGFJ31 then TGFf32 does, however, TGFf31 and TGFI33 share similar
binding affinities to the receptors, whereas TGFf32 binds with 100-1000 times lower
affinity and at different residues with the assistance of a co-receptor (TGFI3RIII or 13-
Glycan). 15,89
We first compared the biological activities of human recombinant TGF131 and
TGFI33 protein using a standard TGFI3 bioactivity assay. Mink lung epithelial cells
(Mv 1 Lu) are a widely used model for evaluation of the effects of exogenous TGFf3 both
in transcriptional and growth inhibitor assays. 176 We show that both TGFj31 and TGF133
inhibit cell growth of MvlLu cells at the same rate at multiple concentrations. In previous
work from our lab, we have shown that TGFj31 acts as a growth inhibitor in both our
normal prostate epithelial PZ-HPV7 cells and our metastatic prostate cancer DU145 cells,
whereas TGF13 loses its ability to inhibit growth in metastatic cell lines PC3 and TGFI3RII
null LNCaP. This suggests that though DU145 is a metastatic cancer cell line, it may still
contain the ability for TGFf3 to act as a tumor-suppressor in the sense of inhibiting
proliferation. Our PC3 cell line, however, no longer responds to TGF13 inhibitory effects
on proliferation, effectively suggesting TGFI3 is now a tumor promoter in these cells.
This led us to use both the DU145 and PC3 cell lines as a possible model for the elusive
TGF13 “switch” from tumor suppressor to tumor promoter.
With this model, we first compared the effects of the exogenous recombinant
TGF131 and TGF133 proteins on the growth of the prostate cell lines PZ-HPV7, DU145
and PC3. Again, we show that not only do both TGFJ3 isoforms inhibit proliferation of
the normal epithelial PZ-HPV7 cells and the metastatic DU145 cells, but they do so at the
same rate at both 1 and 1 Ong/ml doses. PC3 cell growth was not inhibited by either
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isoform. This not only strengthens the use of DU145 and PC3 cells as a “switch” model,
but shows that both isoforms have similar biological activity on proliferation of cells in
multiple normal and metastatic cell lines. Any differences seen between TGFI3 1 and
TGFI33 are not due to differential potencies on growth inhibition.
When comparing the effects of TGFf3 1 and TGFf33 on the motility and invasive
abilities of three metastatic prostate cancer cell lines, DU145, PC3 and LNCaP cells, it is
important to note that both DU145 and PC3 cells express TGFI31 and TGFI33 as well as
all receptors and Smad proteins, whereas LNCaP lacks the TGFI3RII, a necessary receptor
for TGFf3 signaling. However, while both TGFI3 isoforms induced migratory and invasive
behavior in PC3 cells, DU145 and LNCaP cells were unresponsive to both isoforms
under identical experimental conditions. Of the two isoforms that induced migration and
invasion of PC3 cells, TGFI33 was much more potent in doing so. The differential and
more potent effects of TGF~33 on invasive behavior of prostate cancer cells are similar to
those previously reported on TGFI3- induced invasiveness of endometrial carcinoma cells.
27 Again, these differences do not appear to be a consequence of differential bioactivities
of the two recombinant proteins, since no differences were observed in the effects of the
two isoforms on cell proliferation.
In both in vitro migration and invasion, cells require the ability to move across a
gradient, whether it be on a plastic surface (scratch wound assay) or in an insert with a
pourous membrane and an extracellular matrix (invasion assay). For invasion, however,
not only do the cells need the ability to move, but to degrade or displace the components
of an extracellular matrix (ECM) such as Matrigel, which mimics the in vivo ECM. There
have been multiple studies showing the isoform-specific differences in mammalian
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embryos versus adult mammals in regards to wound healing, a process that requires both
growth and motility of surrounding epithelial cells. 177 In these studies, it is shown that
mammalian embryos had wound healing abilities with no scarring while exhibiting high
amounts of TGFI33 and that the addition of exogenous TGFI33 reduced scarring in both
adult mice and in man. 15, 178-181 The role of TGFf33 in wound healing, specifically
whether TGFf33 induces required motility or other processes such as cytoskeleton
formation or angiogenesis, is still elusive. As for the process of invasion, the
extracellular matrix (ECM) is an important determinant of cellular behavior including
regulation of cellular adhesion, migration, and proliferation. 182 TGFI3 has long been
known to play diverse roles in both the production and degradation of the ECM, however
little is known about the isoform-specificity of this control. Taken together, these studies
suggest that isoform-specific functions such as TGFI33 acting in a more potent manner
then TGFI31 in both migration and invasion, may be doing so at numerous biological
levels and affecting multiple processes and pathways.
Prior studies have revealed that TGFI3 isoform-specific effects can be both
dependent or independent of Smad signaling depending on the context in which it is
studied. 27,35,36 Using small molecule inhibitors, we wanted to determine whether TGFf3
isoform-induced migration and invasion in PC3 cells was TGFI3RI or Smad3 dependent.
SB43 1542, a small molecule TGFf3RI inhibitor, is a well characterized inhibitor of
activin receptor-like kinase (ALK5) as well ALK4 and ALK7, which are highly similar in
parts of their structure but does not affect other ALK family members. ~ It is known
to inhibit TGFI3 signaling via competitive ATP binding of the serine/threonine kinase
which, in turn, inhibits Smad3 phosphorylation and has no effect on non-Smad pathways
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such as the MAP-kinase pathway. 183 Another small molecule inhibitor of TGFI3 activity
is SIS3, characterized as a specific inhibitor of TGF-131/ALK-5 induced phosphorylation
of Smad3 and interaction of Smad3 and Smad ~ 184 It is also known not to affect Smad 2
phosphorylation, expression of other Smads and activation of multiple MAP-Kinase
pathway components; however the exact mechanism by which it is a selective inhibitor of
Smad 3 alone is not clear. Our study indicates that the TGFf3 isoform-specific increase of
migration and invasion is both TGFI3RI and Smad3 dependent in PC3 cells. Any isoform
specific activity between TGFI31 and TGFI33 requires activation of the canonical TGFI3
pathway receptor I and the phosphorylation of Smad 3 before it can induce migration and
invasion. This suggests that the differential activity of TGFI3 1 and TGFf33 on migration
and invasion may lie in the activation of a different pathway, specifically a pathway that
is well known to be involved in cancer metastasis and can be activated by TGF~3. This led
us to look at the P13-Kinase and MAP-Kinase pathways.
The P13-Kinase pathway has been shown to play an essential role in the migration
and invasion of many cell types. Previous studies indicate that TGFf3 can activate P13-
Kinase, as shown by increased phosphorylation of AKT, leading to increased invasion of
cancer cells. 27,32-36 In keeping with these studies, our results indicate that the P13-Kinase
pathway is essential for both TGFI31 and TGFI33 induced migration and invasion.
LY294002 is a P13-Kinase inhibitor of the p1 lOcL, p1108 and p1 1013 subuinits which
inactivate P13-Kinase leading to decreased phosphorylation of AKT5~473. 185, 186 Though
it is a commonly used P13 -Kinase inhibitor, it is known to also have a broad inhibitory
profile across different classes of P13-Kinases as well as P13-Kinase-independent effects
such as inhibition of Ca2~ signaling and transcription factors such as NF-kB. 185, 187, 188
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Pharmacological inhibition of P13-Kinase via LY294002 blocked TGFf3 isoform-induced
movement of PC3 cells indicating P13 -Kinase activation is required for TGFI3 induced
migration and invasion. To support this assumption, both TGFf3 isoforms also caused an
increase in the phosphorylation of AKT in PC3 cells, with TGFf33 being more potent than
TGFI31. This TGFI3 isoform-induced phosphorylation of AKT was TGF~3RI, Smad3 and
PL3-Kinase dependent. We also show that not only do both isoforms induced
phosphorylation of Smad 2 and Smad 3, but that this phosphorylation is indeed TGFI3RI
and Smad3 dependent. Inhibition of the P13-Kinase pathway did not affect TGFI3 isoform
induced phosphorylation of both Smads.
Other non-Smad pathway that has been implicated in the progression of multiple
cancer types are the mitogen-activated protein kinase (MAP-Kinase) pathways. 145, 146
MAPKs are protein Serine/Threonine kinases that are involved in wide range of cellular
responses including motility and apoptosis. 147 Of the multiple MAP-Kinases that have
been characterized, we focused on the conventional extracellular signal-regulated kinases
1/2 (ERK 1/2). ERK 1 and ERK2 are activated in response to multiple stimuli including
insulin and by growth factors such as epidermal growth factor (EGF) and TGFf3, although
the exact mechanism by which TGFI3 activates MAP-kinase pathways is still unresolved.
147, 162, 189, 190 TGFI31 slightly induced the phosphorylation of ERK2 (p42) whereas
TGFI33 did not. When an inhibitor of ERKJ MAP-Kinase MEK1/2 (PD98059) was
added, all phosphorylation of ERK1/2 was blocked. Inhibiting the ERKJMAP-Kinase
pathway also did not affect the TGFI3 isoform-induced phosphorylation of AKT,
suggesting that there is no cross-talk or requirement for ERK/MAP-Kinase for TGFJ3-
induced activation of the P13-Kinase pathway. However, blocking the ERKIMAP-Kinase
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pathway inhibited all migration of PC3 cells with and without the presence of TGFI31 or
TGFI33. Taken together, our data shows that the TGFI3 isoform effects on increased
migration and invasion requires both the canonical TGF~3 pathway and the P13-Kinase
pathway, though the activation of the P13-Kinase pathway is not necessary for TGFI3
induced phosphorylation of Smads. Motility of these cells, with or without exogenous
TGFI3 isoform-induced movement, also requires an active ERK/MAP-Kinase pathway.
These results, along with previous studies, confirm a novel isoform-specific role
of TGFI3 in the migration and invasion of the metastatic PC3 prostate cancer cells which
are dependent on the activation of the P13 -Kinase pathway. We did not see similar effects
of TGFI3 isoforms on activation of P13-kinase and AKT phosphorylation in DU145 and
LNCaP cells, indicating that lack of this response may be responsible for lack of TGFI3
effects on migration of these cells. It is tempting to speculate that the ability of TGFI3 to
activate P13-kinase signaling may be pre-requisite for the induction of invasive behavior
in more advanced stages of prostate cancers and may represent the “switch” from anti
tumorigenic to tumor-promoter role of TGFI3.
There are multiple studies on the effect of TGFI3-P13-Kinase activity on both
normal and diseased tissues such as cancer. It is clear that TGFI3 rapidly activates the P13-
Kinase pathway and its downstream target, AKT in multiple cell types. 32, 34, 138 TGFI3RII
has been shown to be associated with p85, the regulatory subunit of P13-Kinase, and that
an association of the TGFj3RI with p85 is required for the activation of P13-Kinase
stimulation by TGFf3. 141 Additionally, inhibition of TGFf3RI activity using a small
molecule inhibitor prevented TGFI3-induced activation of AKT by P13-Kinase. 32,33
Unfortunately, the exact mechanism by which TGFI3 isoforms differentially activate AKT
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and induce motility and invasion is still unknown. One possible contributor in differential
effects of TGFI3 on activation of P13-Kinase in DU145, LNCaP and PC3 cells may be the
Phosphatase and Tensin Homolog (PTEN), which inhibits P13-kinase dependent
phosphorylation of AKT. PTEN has been shown to be mutated in many cancers which
can lead to higher basal levels of pAKT ser473 and increased survival of cells. 31, 125, 133
PTEN is active in the DU145 cell line, but is mutated and biologically inactive in PC3
cells and absent from LNCaP cells altogether. 172-175 Although LNCaP cells have higher
basal levels of pAKT, we did not observe any effects of TGFI3 on pAKT ser473 due to
lack of TGFJ3 signaling in these cells. It is therefore possible that a PTEN mutation
leading to loss of AKT regulation, along with the ability of ligand-activated TGFI3
receptors to activate the P13 -Kinase pathway through the TGFI3R-p85 association can
pLay a role in TGFI3 effects on activation of P13-kinase in prostate cancer cells and that
TGFI3- dependent invasive and metastatic behavior may be more pronounced in patients
where the tumor cells harbor PTEN mutations. This suggests that PTEN and, ultimately,
the P13-Kinase pathway may have a role in the TGFI3 isoform-induced migration and
invasion and the TGFI3 “switch” from anti- to pro-tumorigenic cytokine in prostate
cancer. As for the differences in activity ofTGFI31 and TGFf33, very little is known and it
is recently becoming apparent that these ligands are expressed and operate in a
differential manner depending on the context of the cell. Elucidating the mechanism by




In conclusion, these results, along with previous studies, confirm an isoform
specific role of TGFI3 in the migration and invasion of the metastatic PC3 prostate cancer
cell line. These effects are mediated by both TGFI3RI and Smad3 dependent activation of
the P13-Kinase pathway. We did not see the same effects of TGFI3 isoforms in the
metastatic DU145 or LNCaP cell line, suggesting a cell-line model of a TGFI3 “switch”
from anti-tumorigenic to tumor-promoter, possibly through the activation of the P13-
Kinase pathway. One possible contributor to TGFf3 differential effects and activation of
P13-Kinase in this model is Phosphatase and Tensin Homolog (PTEN), which assists in
the regulation of the phosphorylation of AKT. PTEN has been shown to be mutated in
many cancers which can lead to higher basal levels of pAKT ser473 and increased survival
of cells. PTEN is active in the DU145 cell line, but is mutated in PC3 cells. We show that
basal pAKT ser473 levels are undetectable in DU145 under these experimental conditions,
even with the addition of TGFI3 isoforms. This suggests PTEN and, ultimately, the P13-
Kinase pathway may have a role in the TGFI3 isoform-induced motility and the TGFI3




L.eadlng New Cancer Cases and Deaths —2012 EstImates
Estimated (‘few Caser Estimated Deaths
Male Female Male Female
Prostate Breast Lung & bronchus Lung & bronchus
241.740(29%) 226.870(29%) 87,750(29%) 72.590(26%)
Lung & bronchus Lung & bronchus Prostate Breast
116.470 (14%~ 109,690(14%) 28,170(9%) 39.510(14%)
Colon & rectum Colon & rectum Colon & rectum Colon & rectum
73.420(9%) 70.040(9%) 26,470(9%) 25,220(9%)
Urinary bladder Uterine corpus Pancreas Pancreas
55,600(7%) 47,130(6%) 18,850(6%) 18,540 (7%)
Melanonsa of the skin Thyroid Liver & intrahepatic bile duct Ovary
44250(5%) 43,210(5%) 13,980(5%) 15,509(6%)
Kidney & renal pelvis Melanoma of the skin Leukemia Leukemia
40.250(5%) 32.000(4%) 13.500(4%) 10,040(4%)
Non-Hodgkin lymphoma Non-Hodgkin lyrrsphoma Esophagus Non-Hodgkin lymphoma
38,16.3(4%) 31,970(4%) 12,040(4%) 8,620(3%)
Oral cavity 8 pharyns Kidney & renal pe(v~is Urinary bladder Uterine corpus
28,540(3%) 24,520(3%) 10,510(3%) 8,010(3%)
Leukemia Ovary Non-Hodgkin lymphoma Liver 8 intrahepatic bile du:i
26,830(3%) 22,280(3%) 10.320(3%) 6.570(2%)
Pancreas Pancreas Kidney 8 renal pelvs Bran & other nervous system
22,090(3%) 21,830(3%) 8,650(3%) 5.980(2%)
All sites All sites All sites All sites
848,170 (100%) 790,740 (100%) 301,870(100%) 275,370 (100%)
kscluces ceis arc squannus cr8 skin cancers and in situ carc’rcrra escrpt urinary bladder
oZtt. Ane’crr CalcF 5c’cety. Inc., Su’vellance tesesrct










Primary tumor 1. Invasion
Secondary tumor
Figure 2: The Metastatic Cascade (Scheel et al., 2012)
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Figure 3
1 ALLyiNYcEJ<NLE~ENr~:VRPzY I upRcDLc;Wxwv~rK(iyyANpr:sI:~c:pyLksALrmsT ~ TGFI33
A IDAAYC RFcVQI)Nr::: I I I)FKRD 1GW KW 1 hK IKGY NAN FCWJA(.’ PY I4WSSI IQHSR ~0 TGFf~2
1 ALIDT1•IYCESEOtKN’:l;VRcIZY I LE’RI:DLIIWXWI hE[2KIIYHANR: WPCPY WSILLIQYSR €1) TGF[H
t*t: *** .**** *****::**t*t*:**t*** **** *t**• * ** •*
I :YY’/G~.IIKVF~ISN?.iVVKSGK~;S :1 E 1GF133
VLSLYKT INPEASASPCGVSQrLEPLTI YYIGKTPIC EQLsN~1rvKScxcS V TGFI32
El VLALYGQF{NPGASAAPCCVPQALE PLP1VYYV:3R~cPW~EQLSNNI VRSCI≤CS 112 TGFI31
**_*** ** ***-***** **** *-**.*- .**:******:*:*****
Figure 3: Amino acid sequence alignments of human TGF~ isoforms (Laverty et al. 2009)
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Figure 5: The P13-Kinase Pathway (Cell Signaling
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Figure 6



























Figure 6: The Mitogen-Activated Protein Kinase (MAPK) Cascades. (Cell Signaling)
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Table 1: The Origins of the Cell Lines Used
Cell line Origin
PZ-HPV7 epithelial cells from histologically normal adult human prostate
RWPE1 epithelial cells from histologically normal adult human prostate
RWPE2 epithelial cells were derived from RWPE-1 cells by transformation ~th Ki-ras using
the Kirsten murine sarcoma virus (Ki-MuSV)
DU145 prostate carcinoma, derived from the brain of a 69-year old caucasian male.
PC3 prostate adenocarcinorna derived from the bone of a 62-year old caucasian male
LNCaP ~05tate carcinoma, derived from the left supraciavicular lymph node of a 50.-year
old Caucasian male
Table 2. Gene-specific primers used for RT-PCR amplification.
Gene Forwardprimer Reverse primer Size (bp)
TGF~1 5’-cATcAGAGcTCCGAGAAGCG-3’ 5’-GCTAAGGCGAAAGC~CTCA -3’ 250
TGF~2 5’-ACAAMTAGACATGCCGCCC -3’ 5’-GCTGTCGATGTAGCGCTGG-3’ 250
TGFI~3 5’-TGTCAcACCmCAGCCCAA -3’ 5’-TCCAAGTTGCGGAAGCAGT-3’ 250
TGF~RI 5’-CGTrCGTGGrrCCGTGAG-3’ 5’-CAATGGTATCTGTGGCTGAAT-3 378
TGF~3RU 5’-GATGCTGCTTCTCCAAAGTG-3’ 5’-TCTGTGrrGTGGYrGATGTTG-3’ 376
TGF~3RflI 5’-CTAAGTGTGTGCCTCCTGACG-3’ 5’-CAAACGCAATGCCCATCACG -3’ 216
Smad2 5’-CT’ITI’GTTGTGTAAGCTCTCACTG-3’ 5’-GACCUCTACCACmCAGAGTTG-3’ 247
Smad3 5’-GGGATACCAGCAGCAAGAGAG-3’ 5’-AflGTGAAGACGGTTACCTGAAAG-3’ 201
Smad4 5’-TTGCGTCAGTGTCATCGACAG-3’ 5’-CCAGCCITfCACAAAACTCATCC-3’ 209
Smad7 5’-AATATTTTCCTCCTGAGTGCTTGC-3 5’-AITTCTGCUCCCCTCTTCCTATC-3’ 222










Figure 7: mRNA expression of TGFI3 isoforms and signaling components in prostate cell lines. Semi-
quantitative RT-PCR was performed using RNA from PZ-HPV7, RWPE1, RWPE2, DU145, PC3, PC3M,
and LNCaP cells to determine relative mRNA levels of TGFf3 isoforms (TGFI3I, 2 and 3), TGFf3 receptors
















Figure 8: Protein expression of TGFI3 isoforms in prostate cell lines.western blot analysis was performed to
probe for TGFI3 isoforms (TGFI3I, 2 and 3) in total cell lysates from PZ-HPV7, RWPEI, RWPE2, DU145,





Figure 9: Protein Expression of the TGFf3RII in Prostate Cancer Cell lines. Western blot analysis was
performed to determine relative protein levels of TGFf3RII in LNCaP, DU 145 and PC3 cells. Western blots

















Figure 10: Mink Lung Cell (MVILu) TGFf3 Bioactivity Assay. MvlLu mink lung epithelial cells were used
as target cells for the detection of any differences in recombinant TGFII isoform bioactivity using Cell











































































































Figure 13: Dose dependent effects of TGFfI 1 and TGFf3 3 on proliferation of PC3 prostate cancer cells.









Figure 14: Effects ofTGFJ3I and TGFf33 on migration of PC3 prostate cancer cells. The migratory
properties of PC3 were measured using a scratch wound assay. Cells were cultured overnight and scratched
with a 200iil pipette tip. Culture media were replaced with MEM or RPMI (containing O.l%FBS) and the
cells were treated with TGFI3 I or TGFf33 (1 nglml) for 48h. Images of the scratch area were recorded at











Figure 15: Effects of TGFI3I and TGFI33 on migration of DU145 prostate cancer cells. The migratory
properties of DU145 were measured using a scratch wound assay. Cells were cultured overnight and
scratched with a 200 jil pipette tip. Culture media were replaced with MEM or RPMI (containing
O.l%FBS) and the cells were treated with TGF~1 or T0F133 (Ing/mI) for 48h. Images of the scratch area









Figure 16: Effects ofTGFI31 and TGFJ33 on migration of LNCaP prostate cancer cells. The migratory
properties of LNCaP were measured using a scratch wound assay. Cells were cultured overnight and
scratched with a 200 jil pipette tip. Culture media were replaced with MEM or RPMI (containing
0.1%FBS) and the cells were treated with TGFI3I or TGFf33 (Ing/mi) for 48h. Images of the scratch area








Figure 17: The invasive properties of PC3 cells were measured using the BD BioCoat Matrigel Invasion
inserts. Cells were treated with different concentrations of TGFf3I or TGFII3 and allowed to invade through
a porous membrane coated with Matrigel for 48h. Pictures were taken in five different fields for average





Figure 18: Number of invading PC3 cells through Matrigel after treatment with TGFI3 1 or TGFI33 for 48h.
Each bar represents Mean ± SEM from 4 independent experiments. *Significantly different (P<O.05;

















Figure 19: The invasive properties of DU 145 cells were measured using the BD BioCoat Matrigel Invasion
inserts. Cells were treated with different concentrations of TGFJ3I or TGFfI3 and allowed to invade through
a porous membrane coated with Matrigel for 48h. Pictures were taken in five different fields for average





Control {~hr1 TGF~i {4B~ hr} TGF~3{4B hr)
Figure 20: The effect ofTGFI3I (1 ng!ml) and TGFf33 (1 nglml) on migration of PC3 cells in the presence
of inhibitor of TGFf3 RI (SB43 1542). Scratch wound assays were performed following treatment with






Control (48 hr~ TGF~1 (48 hr) TGF~3 (48 hr)
Figure 21: The effect ofTGFI31 (1 ng/ml) and TGF~3 (1 nglml) on migration of PC3 cells in the presence
of inhibitor of Smad3 (SIS3). Scratch wound assays were performed following treatment with TGFf3





Control (48 hr) TGF~1 (48 hr) TGF(~3 (48 1w)
Figure 22: The effect ofTGF~31 (1 ng/ml) and TGFj33 (1 ng/ml) on migration of PC3 cells in the presence
of inhibitor of TGF P13-kinase (LY294002). Scratch wound assays were performed following treatment
with TGFj3 isoforms for 48h in the presence or absence of specific inhibitors. Pictures were taken at 1 Ox
magnification.
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Figure 23: Number of migrating PC3cells after various treatments. Each bar represents Mean ± SEM from
three independent experiments, a: statistically significant (p<O.O5) from untreated controls, b: statistically




























Control(4Shr) TGF~1(48hr) TGF~3 (48 hr)
Figure 24: The effect ofTGFf3l (1 ng/ml) and TGFj33 (1 ng/ml) on invasion of PC3 cells in the presence of
inhibitor of TGFf3 RI (SB43 1542). Invasion assays were performed following treatment with TGFf3





Control (48 hr) TGF~31(48hr) TGFI33 (48 hr)
Figure 25: The effect of TGFI3 1(1 ng/ml) and TGFI33 (1 ng/ml) on invasion of PC3 cells in the presence of
inhibitor of Smad3 (SIS3). Invasion assays were performed following treatment with TGFj3 isoforms for





Control (48 hr) TGF~1 (48 hr) TGF~3(48hr)
Figure 26: The effect of TGFI3 1 (1 ng/ml) and TGFj33 (1 ng/ml) on invasion of PC3 cells in the presence of
inhibitor of TGF P13-kinase (LY294002). Invasion assays were performed following treatment with TGFI3
isoforms for 48h in the presence or absence of specific inhibitors. Pictures were taken at lOx magnification.
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Figure 27: Number of invading PC3 cells after various treatments. Each bar represents Mean ± SEM from
three independent experiments, a: statistically significant (p<O.O5) from untreated controls, b: statistically
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Figure 28: Comparative expression of phosphorylation of AKT ser473 in prostate cell lines. Total (PAN)
















Figure 29: Comparative effects of TGF~3 I and TGFI33 on phosphorylation of AKT ser473 in PC3, cells after
treatment with the two isoforms over multiple time points. Total (PAN) AKT and 13-actin were used as
loading controls. Data is presented from a representative experiment.
C 5 15 30
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Figure 30: Comparative effects of TGFI3 1 and TGFf33 on phosphorylation of AKT ser473 in PC3 cells after




















Figure 31: Band density analysis of pAKT~473 in PC3 cells after treatment with TGFI3 isoforms for 15 or
60 mm. Each band density was normalized by density of 13-actin bands. Each bar represents Mean ± SE









Figure 32: Comparative effects ofTGF~31 and TGFI33 on phosphorylation of AKT~473 in DU145 cells








Figure 33: Comparative effects of TGFI3 1 and TGF~3 3 on phosphorylation of ~ in LNCaP cells

















Figure 34: Effects of TGFJ3 1 and TGF~33 on phosphorylation of AKT ser473, in PC3 cells in the presence of
inhibitor of TGFI3RJ (SB431542). PC3 cells were incubated with specific inhibitor for 30 mm followed by










Figure 35: Effects ofTGFI3I and TGFf33 on phosphorylation of AKT~~473 in PC3 cells in the presence of
inhibitor of Smad3 (SIS3). PC3 cells were incubated with specific inhibitor for 30 mm followed by










Figure 36: Effects of TGFI3 I and TGFII3 on phosphorylation of AKT ser473 in PC3~ cells in the presence of
inhibitor P13-Kinase inhibitor (LY294002). PC3 cells were incubated with specific inhibitors for 30 mm
followed by treatment with TGFfII or TGFI33 (5 ng/ml) for 60 mm. Cells treated with EGF ( 5 ng/ml) were










Figure 37: Effects of TGFI3 1 and TGFI33 on phosphorylation of Smad2 and Smad3 in PC3 cells. PC3 cells











Figure 38: Effects of TGFf3 I and TGFI33 on phosphorylation of Smad2 and Smad3 in PC3 cells in the
presence of inhibitor of TGFf3RI (SB43 1542). PC3 cells were incubated with specific inhibitor for 30 mm











Figure 39: Effects of TGFf3 1 and TGFI33 on phosphorylation of Smad2 and Smad3 in PC3 cells in the
presence of inhibitor of Smad3 (SIS3). PC3 cells were incubated with specific inhibitor for 30 mm










Figure 40: Effects of TGFI3 I and TGFf33 on phosphorylation of Smad2 and Smad3 in PC3 cells in the
presence of inhibitor of P13-Kinase inhibitor (LY294002). PC3 cells were incubated with specific inhibitor
for 30 mm followed by treatment with TGF~1 or TGFI33 (5 ng/ml) for 60m.Total Smad2/3 and f3-actin












Figure 41: The effects ofTGFj3l or TG933 on the phosphorylation of ERK, a downstream target of the
Mitogen-Activated Protein Kinase Pathway. PC3 cells were treated with TGFI31 or TGFJ33 (5nglml) for 60
mm in the presence or absence of MAPK inhibitor PD98059 and probed for pERK. Total ERK and 13-actin










Figure 42: The effects of MAPK inhibitor PD98059 on the TGFf3I or TGF~3 induced phosphorylation of
AKT~473 in PC3 cells. PC3 cells were incubated with specific inhibitor for 30 mm followed by treatment










Figure 43: The effect ofTGFf3l (1 ng/ml) and TGFf33 (1 nglml) on migration of PC3 cells in the presence
of inhibitor of MAPK (PD98059). Scratch wound assays were performed following treatment with TGF~3
isoforms for 48h in the presence or absence of specific inhibitors. Pictures were taken at I Ox magnification.
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